HomeAI · summaries
Storia in 3 fonti
Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics
The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering a patient's DNA
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Lilly, Ascidian link up in RNA exon editing pact
Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.
- ·
endpoints.news
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup.
